Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

被引：0
|
作者：
Wainberg, Zev A.
Bendell, Johanna C.
Lenz, Heinz-Josef
Baron, Ari David
Berlin, Jordan
Bessudo, Alberto
Bruetman, Daniel
Chung, Ki Y.
Park, Haeseong
Patel, Manish R.
Adewoye, Adeboye H.
Liu, JieJane
Patel, Ravindranath
Shah, Manish A.
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] USC, Keck Sch Med, Los Angeles, CA USA
[4] Calif Pacif Med Ctr Res Inst, San Francisco, CA USA
[5] Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN USA
[6] Calif Canc Care Associates Res & Excellence, Encinitas, CA USA
[7] Goshen Ctr Canc Care, Goshen, IN USA
[8] Greenville Hlth Syst Canc Inst, Greenville, SC USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[11] Gilead Sci Inc, Foster City, CA USA
[12] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[13] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    ANNALS OF ONCOLOGY, 2021, 32 : S321 - S321
  • [32] Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study
    Bennouna, Jaafar
    Borg, Christophe
    Delord, Jean-Pierre
    Husseini, Faress
    Trillet-Lenoir, Veronique
    Faroux, Roger
    Francois, Eric
    Ychou, Marc
    Goldwasser, Francois
    Bouche, Olivier
    Senellart, Helene
    Kraemer, Sandrine
    Douillard, Jean-Yves
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 38 - 44
  • [33] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
    Zhang, Jing
    Yang, Wenwei
    Liu, Junbao
    Wang, Nan
    Ren, Zhaoying
    Yang, Tingting
    Xie, Gongli
    Wu, Guifu
    Sun, Yongkun
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
  • [34] A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer.
    Li, Chunjie
    Noonan, Anne M.
    Hays, John L.
    Roychowdhury, Sameek
    Malalur, Pannaga G.
    Elkhatib, Rifat T.
    Manne, Ashish
    Mittra, Arjun
    Rahman, Shafia
    Phelps, Mitch A.
    Liang, Beiyuan
    Storts, Hadyen
    Khan, Misbah
    Zhang, Evan
    Zheng, Xinru
    Miles, Wayne
    Wang, Jing
    Jin, Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 101 - 101
  • [35] PANITUMUMAB WITH FOLFIRI VS FOLFIRI ALONE: A RANDOMISED PHASE 3 STUDY FOR THE SECOND LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Andre, T.
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    ANNALS OF ONCOLOGY, 2010, 21 : I13 - I13
  • [36] A single center phase 2 study of anti-PD-1 antibody plus bevacizumab and FOLFIRI as second-line treatment for patients with MSI-H metastatic colorectal cancer.
    Li, Hongli
    Ning, Tao
    Zhang, Le
    Ge, Shaohua
    Yang, Yuchong
    Bai, Ming
    Wang, Xia
    Ji, Zhi
    Liu, Rui
    Deng, Ting
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15541 - E15541
  • [37] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    Macarulla, T.
    Cervantes, A.
    Tabernero, J.
    Rosello, S.
    Van Cutsem, E.
    Tejpar, S.
    Prenen, H.
    Martinelli, E.
    Troiani, T.
    Laffranchi, B.
    Jego, V.
    von Richter, O.
    Ciardiello, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1874 - 1881
  • [38] Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
    T Macarulla
    A Cervantes
    J Tabernero
    S Roselló
    E Van Cutsem
    S Tejpar
    H Prenen
    E Martinelli
    T Troiani
    B Laffranchi
    V Jego
    O von Richter
    F Ciardiello
    British Journal of Cancer, 2015, 112 : 1874 - 1881
  • [39] A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ozaka, Masato
    Ogura, Mariko
    Chin, Keisho
    Yamaguchi, Toshiharu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1653 - 1662
  • [40] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
12345